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Abstract
Heat shock proteins (Hsps) are well appreciated as intrinsic protectors of cardiomyocytes against numerous stresses. Recent
studies have indicated that Hsp20 (HspB6), a small heat shock protein, was increased in blood from cardiomyopathic
hamsters. However, the exact source of the increased circulating Hsp20 and its potential role remain obscure. In this study,
we observed that the circulating Hsp20 was increased in a transgenic mouse model with cardiac-specific overexpression of
Hsp20, compared with wild-type mice, suggesting its origin from cardiomyocytes. Consistently, culture media harvested
from Hsp20-overexpressing cardiomyocytes by Ad.Hsp20 infection contained an increased amount of Hsp20, compared to
control media. Furthermore, we identified that Hsp20 was secreted through exosomes, independent of the endoplasmic
reticulum-Golgi pathway. To investigate whether extracellular Hsp20 promotes angiogenesis, we treated human umbilical
vein endothelial cells (HUVECs) with recombinant human Hsp20 protein, and observed that Hsp20 dose-dependently
promoted HUVEC proliferation, migration and tube formation. Moreover, a protein binding assay and immunostaining
revealed an interaction between Hsp20 and VEGFR2. Accordingly, stimulatory effects of Hsp20 on HUVECs were blocked by
a VEGFR2 neutralizing antibody and CBO-P11 (a VEGFR inhibitor). These in vitro data are consistent with the in vivo findings
that capillary density was significantly enhanced in Hsp20-overexpressing hearts, compared to non-transgenic hearts.
Collectively, our findings demonstrate that Hsp20 serves as a novel cardiokine in regulating myocardial angiogenesis
through activation of the VEGFR signaling cascade.
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Introduction
It is well appreciated that heat shock proteins (Hsps) are activated
in the mammalian heart in response to numerous physiological or
pathological stresses and consequently, provide cardioprotection
[1,2]. Hsp20, also referred to as HspB6, belongs to a small heat shock
protein family (15–30 kDa) which includes at least 10 members
(HspB1–B10) [3,4]. While Hsp20 can be detected in various tissues,
it is most highly expressed in muscle cells [3–5]. Over the past years,
our laboratory has shown that elevated intracellular Hsp20 protects
hearts against various stress stimuli including myocardial ischemia/
reperfusion (I/R) injury [6], isoproterenol-triggered cardiac remod-
eling [7], endotoxin-induced myocardial dysfunction [8], and
doxorubicin cardiotoxicity [9]. These salutary effects of Hsp20 are
largely attributed to the inhibition of cardiomyocyte death through
multiple interactions with a-actin, a-actinin, Akt, Bax, NF-kB, 14-3-
3c, phosphodiesterase-4 (PDE4), and apoptosis signal-regulating
kinase 1 (ASK1) [6–14]. Interestingly, we showed that Hsp20-
engineered mesenchymal stem cells (MSCs) augmented the secretion
of growth factors (VEGF, FGF-2, and IGF-1) and promoted
myocardial angiogenesis [15]. However, the mechanistic role of
Hsp20 in cardiac angiogenesis remains obscure.
Recently, a growing number of proteins are found to be secreted
from the heart [16,17]. These heart-derived proteins are now
termed cardiokines [17]. Several experimental approaches have
estimated the number of putative cardiokines to be between 30
and 60 [17]. Importantly, the cardiokines identified so far have
been shown or predicted to play critical roles in maintaining
normal cardiac development and potential repair of damaged/
diseased myocardium [17]. Numerous studies indicate that some
Hsps (i.e. Hsp90, Hsp70, Hsp60, and aB-crystallian) are detectable
outside a variety of cell types including neuronal cells, monocytes,
macrophages, endothelial cells and tumor cells of epithelial origin
[18–22]. However, whether Hsps serve as cardiokines is not well
defined. Notably, Hsp20 is detectable in blood and is believed to
inhibit platelet aggregation [23]. A study by Kozama et al. [24]
further demonstrated that plasma Hsp20 levels were increased in
cardiomyopathic hamsters. Nonetheless, it remains unclear
whether circulating Hsp20 is mainly derived from cardiomyocytes
or from endothelial cells of the coronary vasculature.
In this study, we utilized a mouse model with cardiac-specific
overexpression of Hsp20 to decipher whether circulating Hsp20 is
increased. For the first time, we demonstrated that Hsp20 was
secreted from adult rat cardiomyocytes via exosomes, independent
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of the classical ER-Golgi protein export pathway. Moreover, we
identified what we believe to be a novel function for the
extracellular Hsp20 in hearts as a mediator of angiogenesis
through directly interaction with VEGFR2.
Materials and Methods
Mouse Model, Cell lines, Adenovirus Vectors
All animal protocols conformed to the Guidelines for the Care and
Use of Laboratory Animals prepared by the National Academy of
Sciences and published by the National Institutes of Health, and
were approved by the University of Cincinnati Animal Care and
Use Committee (Animal Welfare Assurance Number: A3295-01).
A transgenic mouse model with cardiac-specific overexpression of
Hsp20 and a recombinant adenovirus vector Ad.Hsp20 were
described previously [6,12]. HEK293 cells (human embryonic
kidney cell line) purchased from the ATCC (Manassas, VA) were
cultured in DMEM supplemented with 10% FBS and 100 mg/ml
penicillin/streptomycin. The HUVECs (human umbilical vein
endothelial cell) (PromoCell, Germany) were maintained in
Endothelial Cell Growth Media with supplementMix and
100 mg/ml penicillin/streptomycin, which did not contain VEGF.
In vivo Ischemia/Reperfusion
Ischemia/reperfusion was performed in male adult mice (FVB/
N, 10–12 weeks old) by transiently ligating the left anterior
descending coronary artery (LAD) for 30 min, followed by
24 hours of reperfusion [6]. Blood samples were collected for
further experiments. Hearts were fixed in 4% paraformaldehyde
and embedded in paraffin for morphological analysis.
ELISA for the Detection of Extracellular Hsp20
Hsp20 in sera or supernatants was detected by an optimized
sandwich ELISA. Briefly, high-binding 96-well ELISA plate (BD
Biosciences) was coated overnight with rabbit polyclonal anti-
Hsp20 (Affinity Bioreagents) in carbonate buffer. Samples or
recombinant mouse Hsp20 protein (EIAab Science) were added
and incubated for 2 h followed by three washes in PBST. Mouse
monoclonal anti-Hsp20 (Fitzgerald) was used as a detection
antibody and incubated for 2 h followed by five washes. Finally,
TMB substrate reagent (BD Biosciences) was added, and
absorbance was read by a microplate reader (Biotek) at 450 nm.
Immunofluorescence Staining
Heart sections (3 mm) were incubated with specific two-mixtures
of Abs: mouse anti-Hsp20 (Fitzgerald)/rabbit anti-VEGFR2
(Acris) for detection of colocalization; rabbit anti-Hsp20 (R&D)/
mouse anti-a-Actin (Sigma-Aldrich) for detection of Hsp20
translocation; and rabbit anti-CD31 (Abbiotec)/mouse anti-a-
Actin antibody for detection of vascular density. Specific binding
of primary Abs was detected using corresponding Alex488- or
Alex594-conjugated secondary Abs (Invitrogen). Immuno-staining
was examined using an Olympus BX41 fluorescence microscope
(Olympus America, Melville, NY), and evaluated using IPP 5.1
and MagnaFire 2.1 software.
Preparation of Adult Rat Cardiomyocytes and Lactate
Dehydrogenase Assay
Rat ventricular myocytes were isolated from adult male Sprague-
Dawley rats (6–8 weeks old) and plated on laminin-coated glass
coverslips or dishes, as described previously [7–9,12,25]. After 2 h,
attached cardiomyocytes were infected with Ad.GFP (control) or
Ad.Hsp20 in diluted media, at a multiplicity of infection (MOI) of
500, for 2 h before addition of suitable volume of culture media. For
isolation of exosomes, culture media were collected after 48 h of
adenoviral infection, when the infection efficiency reached more
than 95%, determined by GFP under fluorescence microscopy.
Cardiomyocyte injury was assessed by measuring Lactate dehydro-
genase (LDH) release using an LDH detection kit, according to the
manufacturer’s instructions (Sigma-Aldrich).
Isolation and Quantitation of Exosomes
Exosomes were collected on ice from 2 ml of adult rat
cardiomyocytes media, using the Exosome precipitation kit
(System Biosciences) according to the manufacturer’s instructions.
The amount of released exosomes was quantified by measuring
the activity of acetylcholine esterase, an enzyme that is specifically
involved in these vesicles [26]. Acetylcholine esterase activity was
assayed as described previously [27]. All samples were plated in
triplicate. The value represents the enzymatic activity after 20 min
of incubation.
HUVEC Proliferation, Migration and Tube Formation
Assays
The assessment of cell proliferation was performed by MTS
assay (CellTiter 96 AQueous One Solution Cell Proliferation
Assay Kit, Promega), as the manufacturer’s instructions. HUVECs
were seeded into 96-well plates at an initial density of 56103 cells/
well. After 2 h, recombinant human Hsp20 protein (US Biological)
was added at various doses for 18–48 h. BSA was added as
control. A curve of cell proliferation was constructed by measuring
cell growth with a microplate reader at 490 nm.
The migration potency of HUVECs was determined by
migration assays using the BD Falcon Cell Culture Insert System
(BD Biosciences), according to the instructions of the manufac-
turer. We used a double-chamber method to determine the effect
of recombinant human Hsp20 protein on HUVEC migration.
HUVEC cells (56104 cells/well) were seeded into the upper
transwell chambers with 8 mm pores, which were then placed into
a 24-well plate in which the Hsp20 protein or medium only
(control) were added. After 6 h of incubation, cells were stained
with Hoechst 33342 (Invitrogen) for 30 min and the upper surface
of transwell chambers was wiped with a cotton swab. Migrating
cells were counted in five random microscopic fields (6200).
The formation of capillary-like structures was assessed in a 24-
well plate using growth factor-reduced Matrigel (BD Biosciences).
For this procedure, HUVECs (36104 cells/well) were plated on
top of Matrigel (500 ml/well) 2 hours before recombinant human
Hsp20 protein was added. After 16 h, cells were fixed in 70%
ethanol and the total tube length was quantified using software
Image-Pro plus 5.1.
VEGFR2/Hsp20 Competitive Binding Assay
The purified VEGFR2 protein (ProSpec) and control protein
(BSA) were diluted to a final concentration of 20 mg/ml with
carbonate coating buffer and a high-binding 96-well ELISA plate
was coated overnight at 4uC with 100 ml of the protein solution.
The solution was removed followed by three washes with PBST.
Then, the plate was incubated with 200 ml of blocking buffer (1%
BSA) at room temperature for 1 h. Recombinant human Hsp20
protein was diluted at various concentrations (1.2, 2.4 and 4.8 mg/
ml) with PBS. Plate was washed three times with PBST and 100 ml
Hsp20 preparations were added and incubated at room
temperature for 2 h. Plate was then washed three times before
anti-Hsp20 antibody (1:5000 dilution in PBS, Fitzgerald) was
added. After 2 h incubation at room temperature followed by
Extracellular Hsp20 Promotes Angiogenesis
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three washes, anti-mouse HRP conjugated secondary antibody
(diluted 1:5000 in PBS) was added and the plate was incubated for
1 h at room temperature. The plate was washed five times with
PBST and 100 ml of TMB substrate reagent was added followed
by a 25-min incubation at room temperature. The plate was read
by a microplate reader (Biotek) at 450 nm as soon as 50 ml stop
solution was added.
Western Blot Analysis
Protein samples were extracted from hearts or cultured
HUVECs, with procedures as described in detail elsewhere. Equal
amounts of protein were subject to SDS-PAGE. Binding of the
primary antibody was detected by peroxidase-conjugated second-
ary antibodies and enhanced chemiluminescence (Amersham),
and bands were quantified with densitometry. The source of
antibodies and dilutions used were as follows: mouse anti-Hsp20
antibody (1:500 dilution, Fitzgerald), mouse anti-p-Akt (1:500
dilution), mouse anti-Akt (1:500 dilution), rabbit anti-p-ERK
(1:500 dilution), and rabbit anti-ERK (1:500 dilution) antibodies
(Cell Signaling). a-Actin (Sigma-Aldrich) or b-actin (Cell Signal-
ing) was used as an internal control.
Statistical Analysis
Data are presented as mean 6 SD. Comparisons were made by
Student’s t test as appropriate. A value of P,0.05 was considered
statistically significant.
Results
Hsp20 can be actively released from the myocardium
in vivo
It has been shown that plasma levels of Hsp20 in cadrdiomyo-
pathic hamsters were markedly elevated [24]. To investigate
whether circulating Hsp20 is increased in animals subjected to
myocardial ischemia/reperfusion (I/R), 12-weeks old mice (FVB/
N) underwent in vivo 30-min myocardial ischemia, via coronary
artery occlusion, followed by 24-h reperfusion. Subsequently, sera
were collected and levels of Hsp20 were measured using an
optimized Sandwich ELISA. As expected, levels of circulating
Hsp20 were increased by 3.4-fold in mice upon myocardial I/R
insults, compared to the sham operation group (Figure 1A). Given
that myocardial ischemia/reperfusion causes cell damage, the
increased circulating Hsp20 may be derived from the injured
Figure 1. Hsp20 is secreted from cardiomyocytes in vivo. (A) The serum Hsp20 level was increased in response to in vivo 30 min-LAD occlusion
followed by 24 h-reperfusion. Cardiac-specific overexpression of Hsp20 increased the Hsp20 concentration in the serum under basal and myocardial
ischemia/reperfusion conditions. (n = 6; *, p,0.05 vs. WTs; #, p,0.05 vs. Sham groups). (B) The levels of Hsp20 in hearts from Hsp20-transgenic mice
were determined by Western blot. a-Actin was used as an internal control (n = 4). (C) Myocardial ischemia/reperfusion stimulated the translocation of
Hsp20 to the cardiomyocyte membrane, which was detected by fluorescence microscopy. Images are representative sections from four mice per
group (green, Hsp20; red, a-Actin; Scale bar, 100 mm). (D) Quantitative data for expression of Hsp20 was evaluated using IPP 5.1 (n = 4; *, p,0.05 vs.
WTs; #, p,0.05 vs. Sham groups).
doi:10.1371/journal.pone.0032765.g001
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myocardium. Therefore, it is still uncertain whether Hsp20 is
passively or actively secreted from cardiomyocytes or endothelial
cells.
Hence, to clarify the origin of circulating Hsp20, we employed a
transgenic (TG) mouse model with cardiac-specific overexpression
of Hsp20 (10-fold, Figure 1B). Our results indicate that serum
levels of Hsp20 was increased by 57% in the Hsp20 TG mice,
compared to wild-type (WT) mice (Figure 1A). These data suggest
that intracellular Hsp20 can be actively released outside
cardiomyocytes into the bloodstream. Consistently, we observed
that serum Hsp20 was dramatically elevated by 2.2-fold in Hsp20-
TG mice upon myocardial I/R stress, compared with WT controls
(Figure 1A). Furthermore, we determined the distribution of
Hsp20 in hearts upon I/R. Immunostaining results demonstrated
that myocardial I/R induced accumulation of Hsp20 on the
membrane of cardiomyocytes with more significant in TGs,
compared to WT samples (Figure 2C and D). These results
indicate that enhanced expression of Hsp20 in the heart
(genetically or pathologically) augments extracellular Hsp20.
Hsp20 is secreted from cultured adult cardiomyocytes in
vitro
To confirm our in vivo findings that elevated intracellular Hsp20
can be secreted outside cells, we performed further studies using in
vitro cultured adult rat ventricular myocytes in a well controlled
experimental setting. Adult rat cardiomyocytes were infected with
Ad.Hsp20 and 48 h later, 10 or 20 mM of H2O2 was added to
these myocytes for 2 h. Subsequently, culture supernatant was
harvested for measuring the Hsp20 content. We observed that
there was a small amount of Hsp20 released from unstressed
cardiac myocytes, and the amount was too low to tell the
difference between Ad.GFP-cells (31 pg/105 cells/ml) and
Ad.Hsp20-cells (40 pg/105 cells/ml) (Figure 2A). However, upon
addition of a mild stress with a low dose of H2O2 (20 mM) for 2 h,
the content of Hsp20 in the culture supernatant was significantly
increased, with a more pronounced increase seen in Hsp20-
overexpressing myocytes compared to basal conditions (Figure 2A).
Extracellular Hsp20 was reached to 60 pg/105 cells/ml in
Ad.GFP-myocytes, and dramatically increased to 191 pg/105
cells/ml in Ad.Hsp20-myocytes upon H2O2 stimulation
(Figure 2A). Importantly, dosages of H2O2 we used did not cause
any cytotoxic effects, because the concentration of lactate
dehydrogenase (LDH), a marker of the cell injury, in culture
media was no different among groups (Figure 2B). Together, these
data confirm the in vivo findings showed that Hsp20 was actively
secreted from cardiomyocytes.
Hsp20 is released via exosomes, independent of the
classic protein export pathway
While Hsp20 is detectable outside cells, it remains elusive how
to regulate the release of intracellular Hsp20. Currently, the
endoplasmic reticulum (ER)/Golgi pathway is the most widely
recognized mechanism for protein release from the cell [28].
However, accumulating evidence has established that several heat
shock proteins (i.e. Hsp60, Hsp70 and aB crystalline) are secreted
by a non-classical pathway that involves exosomes [26,29,30].
Therefore, we dissected both the classical ER-Golgi protein export
pathway and alternative secretory pathway in Hsp20-overexpress-
ing myocytes. Pre-treatment with 10 mg/ml Brefeldin A (BFA), an
inhibitor of the classical protein transport pathway [26,27], did not
attenuate the Hsp20 secretion from cardiomyocytes under basal
conditions (Figure 3A). Similarly, low dose H2O2 increased the
release of Hsp20 into the media, which was not blocked by BFA
treatment (Figure 3A). In contrast, the release of Hsp20 from
cardiomyocytes was reduced by both dimethyl amiloride (DMA,
an exosome inhibitor) and Methyl-b-cyclodextrin (MBC, an
inhibitor of lipid raft formation via depletion of membrane
cholesterol) under both basal and hypoxia conditions (Figure 3A).
These results indicate that the release of Hsp20 is dependent on
the formation of exosome/lipid raft.
To further validate the involvement of exosomes in the release
of Hsp20, we isolated exosomes using the Exosome precipitation
kit and measured acetylcholine esterase activity, an exosome
marker. As shown in Figure 3B, both DMA and MBC inhibited
the release of exosomes from cardiac myocytes under basal and
hypoxic conditions, whereas BFA had no effect. These results
indicated that the effect of these three inhibitors on exosome
release parallels their effects on the release of Hsp20, suggesting
that Hsp20 secretion is via exosomes.
Extracellular Hsp20 promotes HUVEC proliferation,
migration and tube formation
Recently, our laboratory has showed that transplantation of
Hsp20-engineered mesenchymal stem cells enhances the paracrine
effects on infarcted hearts, as accompanied with increase in the
vascular density [15]. However, it is unknown whether extracel-
lular Hsp20 functions in cardiac paracrine signaling. Therefore,
we employed human umbilical vein endothelial cells (HUVECs) to
investigate whether extracellular Hsp20 promotes angiogenesis. A
recombinant human Hsp20 protein was added to HUVECs at
various doses (80, 400 and 2000 ng/ml) for 24 h, and BSA was
used as a control. We observed that Hsp20 dose-dependently
Figure 2. Overexpression of Hsp20 in adult cardiomyocytes
enhances its secretion. (A) Mild stress dose-dependently increased
the amount of Hsp20 released from both Ad.GFP and Ad.Hsp20
infected myocytes, and (B) there was no difference in the release of
lactate dehydrogenase (LDH), a marker of necrosis. Similar results were
observed in two additional, independent experiments (*, p,0.05 vs.
Ad.GFP-Control; #, p,0.05 vs. Ad.GFP).
doi:10.1371/journal.pone.0032765.g002
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promoted the HUVEC proliferation, as measured by the MTS
incorporation (Figure 4A). Furthermore, HUVECs were treated
with the Hsp20 protein at a dose of 1000 ng/ml for 18, 24 or 48 h,
the MTS proliferation-assay showed that Hsp20 could also time-
dependently promoted the HUVEC proliferation (Figure 4B).
Using a transwell assay, we found that recombinant human Hsp20
protein increased HUVECs migration by 2.6-fold compared with
the controls. Importantly, no significant difference was observed
between the BSA treatment and non-treated groups (Figures 4C
upper-panel and 4D). Accordingly, the tube-like structures were
dramatically enhanced by 63% with the addition of the Hsp20
protein, whereas the treatment with BSA yielded fewer tube-like
structures (Figures 4C down-panel and 4E). Collectively, these
data indicate that the extracellular Hsp20 can promote angiogen-
esis as evidenced by enhancing proliferation, migration and tube
formation of endothelial cells.
Extracellular Hsp20 promotes angiogenesis by binding
with VEGFR2
It is well appreciated that mitogenesis and migration of
endothelial cells is mainly mediated by VEGFR2 [31]. Addition-
ally, the Hsp20 protein has been predicated to contain several
interactive domains with VEGF, FGF-2 and insulin [15]. Based on
these data, we hypothesized that Hsp20 may interact with the
receptors for these growth factors. To test this hypothesis, we first
developed a competitive protein binding assay to examine whether
Hsp20 binds with VEGFR2. Our results showed that VEGFR2-
coated wells, but not BSA-coated wells, dose-dependently captured
the Hsp20 protein, which were detected by an anti-Hsp20
antibody (Figure 5A). Moreover, immuno-fluorescence staining
revealed that the addition of purified Hsp20 protein not only
induced the expression of VEGFR2, but also co-localized with
VEGFR2 in HUVECs (Figure 5B). Together, these data indicate
that Hsp20 may directly interact with VEGFR2.
To further determine whether Hsp20-mediated actions on
endothelial cells are dependent on VEGFR2, we pre-incubated
HUVECs with a VEGFR2 neutralizing antibody or CBO-P11, a
specific VEGFR inhibitor [32], for 30 min, followed by addition of
the Hsp20 protein. We observed that both the VEGFR2 antibody
and COP-P11 markedly reduced the stimulatory effect of Hsp20
on cell migration by 30% and 26%, respectively (Figure 5C- up
panel and Figure 5D), compared with the IgG control.
Consistently, the activity of Hsp20 on promoting endothelial cell
tube formation was attenuated by pre-treatment with the
neutralizing antibody or CBO-P11 (Figure 5C-downpanel and
Figure 5E). Taken together, these results demonstrate that the
effect of Hsp20 on the HUVEC migration and tube formation is
largely dependent on VEGFR2.
Considering that the activation of Akt and ERK pathways plays
a critical role in VRGFR2-mediated endothelial cell phenotype
[31], we next examined whether extracellular Hsp20 activates the
VEGFR2-mediated downstream signaling. Quantitative results of
western blots showed that levels of phosphorylated Akt were
increased by ,6-fold in HUVECs at 30 min to 1 hour after
treatment with the Hsp20 protein, which were significantly
inhibited by the VEGFR2 neutralizing antibody (Figure 5F and
5G). Likewise, levels of phosphorylated ERK were also elevated at
30 min to 1 hour, but decreased by ,30% with pre-treatment of
the VEGFR2 antibody before the addition of Hsp20 (Figure 5F
and 5G). These results suggest that Hsp20-mediated angiogenesis
is largely associated with the Akt and ERK signaling pathways via
activation of VEGFR2.
Cardiac-specific overexpression of Hsp20 increases
capillary density
Knowing that circulating Hsp20 was increased in Hsp20-TG
mice, and extracellular Hsp20 promoted HUVEC proliferation,
migration and tube formation, it is reasonable to speculate that the
enhanced expression of intracellular Hsp20 could lead to an
augmentation of myocardial angiogenesis. Therefore, we mea-
sured cardiac capillary density by immuno-fluorescence staining
with an antibody to CD31, a specific marker of endothelial cells
[15]. We observed that Hsp20 transgenic hearts revealed a
significant increase in capillary density (122628/mm2), compared
to wild-type hearts (25612/mm2) (Figure 6). These results clearly
indicate that cardiac-specific overexpression of Hsp20 can
promote myocardial angiogenesis through its secretion which
functions via paracrine signaling (Figure 7).
Discussion
Hsp20 is well recognized to act intracellularly as a molecular
chaperone and confers protection against various hazardous
conditions [3–6]. In the present study, we identified that Hsp20
was released from adult cardiomycoytes through exosome-
dependent secretory machinery (Figure 7). Furthermore, we
uncovered that extracellular Hsp20 physically bound to the
VEGF receptor and thereby activated the downstream singling
pathway (i.e. Akt, EKR). As a result, myocardial angiogenesis was
enhanced in Hsp20-overexpressing hearts (Figure 7). To our
Figure 3. Hsp20 is secreted from adult rat cardiomyocytes via
exosomes, independent of the ER-Golgi protein export path-
way. (A) Brefeldin A (BFA), which inhibits the classical protein transport
pathway, did not block Hsp20 release into the media under either basal
or hypoxia conditions (20 mM H2O2). However, the release of Hsp20
from cardiomyocytes was reduced by both dimethyl amiloride (DMA),
an exosome inhibitor, and Methyl-b-cyclodextrin (MBC), an inhibitor of
lipid raft formation via depletion of membrane cholesterol. (B) The
activity of acetylcholine esterase was used to quantify the amount of
exosomes present in the media after various treatments. Similar results
were observed in three additional, independent experiments (*, p,0.05
vs. Basal-Control; #, p,0.05 vs. H2O2-Control).
doi:10.1371/journal.pone.0032765.g003
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knowledge, this is the first report to demonstrate that extarcellular
Hsp20 functions as a VEGF-receptor agonist.
While intracellular Hsp20 was overexpressed by 10-fold in our
cardiac-specific transgenic mice, the circulating Hsp20 was
increased only 57%, compared to non-transgenic mice (Figure 1).
This result indicates that most of Hsp20 is retained inside cells
under the normal physiological state. However, upon hypoxic/
ischemic stress, much more intracellular Hsp20 was translocated
to the cellular membrane or packaged within exosomes (Figure 1)
and subsequently secreted outside cardiomyocytes. Currently,
although it is not clear how Hsp20 participates in the formation of
exosomes, the membranous distribution of Hsp20 may largely
contribute to the component of exosomes. Likewise, a recent study
by Gupta et al. [26] also demonstrated that unstressed cardiomy-
ocytes released Hsp60 but the addition of 2-hour hypoxia,
increased the amount of extracellular Hsp60 without evidence of
necrosis. These data imply that extracellular Hsps may be
physiological alarm signals for myocardial infarction. Interestingly,
while intracellular Hsp60 has an anti-apoptotic role in cardiomy-
ocytes [33], extracellular Hsp60 can precipitate cardiac apoptosis
through activation of Toll-like receptor (TLR)-4 [34]. By contrast,
our previous studies [6–9,12,15] and current data demonstrate
that Hsp20, regardless of location and despite different underlying
mechanisms, consistently elicits a salutary effect in the heart.
Actually, overexpression of Hsp20 in the heart not only resists
stress-triggered cardiomyocyte death via the intrinsic anti-
apoptotic pathways, but also causes increased secretion of Hsp20
outside cardiomyocytes, which may function in autocrine or
paracine signaling, enhancing the survival of cardiomyocytes and
non-cardiomyocytes. Furthermore, the circulating Hsp20 has been
demonstrated to bind to platelets and inhibit their aggregation
[23,24], which may be beneficial for the treatment of ischemic
heart disease. In the present study, we identified a heretofore
unrecognized role of the extracellular Hsp20 in cardiac angiogen-
esis. Given that coronary angiogenesis is instrumental in functional
compensation and restoration of the heart [31,32], increased
capillary density in cardiac-specific Hsp20-overexpressing mice
may provide a new mechanism underlying Hsp20-mediated
protective effects against potential cardiac injury. Taken together,
these data suggest that Hsp20 may serve as a novel cardiokine and
benefit hearts at multiple levels.
Our study did not precisely address several clinical issues
including: whether the Hsp20 protein is stable in the extracellular
environment; whether the Hsp20 protein can be employed to treat
myocardial infarction by exogenous systemic administration; and
what advantage the Hsp20 protein might have over VEGF in
promoting myocardial angiogenesis. Such analysis may fall outside
the scope and intent of this report. However, the data presented
here raise a novel hypothesis that Hsp20-containing exosomes may
have a promising therapeutic application in the treatment of
ischemic heart disease. In addition to the instrumental role of
Hsp20 in the heart [3–15], a number of recent studies have
implicated exosmes as intercellular signalsomes and pharmaco-
logical effectors [35]. First, exosomes are small, plasma-mem-
brane-derived particles (usually 30–100 nm) that can be easily
taken up by the surrounding cells [36]. Second, exosomes secreted
from human mesenchymal stem cells have been shown to reduce
myocardial ischemia/reperfusion injury in animal models [37],
Figure 4. Hsp20 stimulates HUVEC proliferation, migration and capillary-like tube formation. (A) Recombinant human Hsp20 protein
was added to HUVECs at various doses (80–2000 ng/ml) for 24 h. BSA was used as a control. Cell proliferation was determined by MTS. (B) Time-
course effects of the Hsp20 protein(1000 ng/ml) on the HUVEC proliferation. (C) Representative photographs indicated the effects of recombinant
human Hsp20 protein on the trans-well and tube formation of HUVECs. (D) Migration was quantified by counting cells that were moved through the
membrane (Trans-well assay). (E) Tube formation was evaluated by the measurement of relative tube length. Similar results were observed in three
additional, independent experiments (*, p,0.05 vs. Control).
doi:10.1371/journal.pone.0032765.g004
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Figure 5. Extracellular Hsp20 interacts with VEGFR2 and activates its downstream signaling pathways. (A) VEGFR2 coated on a plate
dose-dependently captured the Hsp20 protein, whereas BSA coated did not arrest the Hsp20 protein. (B) Recombinant human Hsp20 protein
Extracellular Hsp20 Promotes Angiogenesis
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and cardiomyocyte progenitor cell-derived exosomes stimulated
migration of endothelial cells [38]. Moreover, in mast cells,
exosomes were demonstrated to communicate a protective signal
to recipient cells during oxidative stress resulting in reduced cell
death [39]. Therefore, it would be expected that Hsp20-containing
exosomes may have combined effects to a great extent in both
extrinsic and intrinsic protective pathways for the heart. Future
studies are needed to clarify this hypothesis.
In conclusion, this study demonstrates that Hsp20, similar to
other cardiokines, is actively released from cardiomyocytes under
both steady state and stressed conditions via exosomes. Our
findings highlight a novel role for Hsp20 in facilitating myocardial
angiogenesis through interaction with VEGFR2, suggesting a
possible novel therapeutic approach to inducing the angiogenic
pathway by Hsp20 gene therapy or administration of Hsp20-
containing exosomes.
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